The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application
Author:
Lee Su-Jun,Shin Jae-Gook
Reference181 articles.
1. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M, Yasar U (2004) Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 76:113–118 2. Ancrenaz V, Desmeules J, James R, Fontana P, Reny JL, Dayer P, Daali Y (2012) The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. Br J Pharmacol 166:2362–2370 3. Au N, Rettie AE (2008) Pharmacogenomics of 4-hydroxycoumarin anticoagulants. Drug Metab Rev 40:355–375 4. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, Nacak M, Roots I (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48:409–415 5. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, Flockhart DA (1995) The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 57:662–669
|
|